Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results

Structure Therapeutics (NASDAQ:GPCR) posted its quarterly earnings results on Monday. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15), FiscalAI reports.

Structure Therapeutics Trading Down 1.7%

GPCR traded down $0.36 on Wednesday, reaching $21.37. The company had a trading volume of 300,816 shares, compared to its average volume of 965,599. The company has a fifty day moving average of $29.51 and a 200-day moving average of $47.10. The company has a market capitalization of $1.49 billion, a P/E ratio of -16.54 and a beta of -1.12. Structure Therapeutics has a one year low of $18.70 and a one year high of $94.90.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several recent research reports. Weiss Ratings raised Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research report on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Finally, HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.91.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.